0 53

Cited 0 times in

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Authors
 Justin F Gainor  ;  Giuseppe Curigliano  ;  Dong-Wan Kim  ;  Dae Ho Lee  ;  Benjamin Besse  ;  Christina S Baik  ;  Robert C Doebele  ;  Philippe A Cassier  ;  Gilberto Lopes  ;  Daniel S W Tan  ;  Elena Garralda  ;  Luis G Paz-Ares  ;  Byoung Chul Cho  ;  Shirish M Gadgeel  ;  Michael Thomas  ;  Stephen V Liu  ;  Matthew H Taylor  ;  Aaron S Mansfield  ;  Viola W Zhu  ;  Corinne Clifford  ;  Hui Zhang  ;  Michael Palmer  ;  Jennifer Green  ;  Christopher D Turner  ;  Vivek Subbiah 
Citation
 LANCET ONCOLOGY, Vol.22(7) : 959-969, 2021-07 
Journal Title
LANCET ONCOLOGY
ISSN
 1470-2045 
Issue Date
2021-07
MeSH
Aged ; Antineoplastic Agents / adverse effects ; Antineoplastic Agents / therapeutic use* ; Biomarkers, Tumor / genetics* ; Carcinoma, Non-Small-Cell Lung / drug therapy* ; Carcinoma, Non-Small-Cell Lung / genetics ; Carcinoma, Non-Small-Cell Lung / pathology ; Female ; Gene Fusion* ; Humans ; Lung Neoplasms / drug therapy* ; Lung Neoplasms / genetics ; Lung Neoplasms / pathology ; Male ; Middle Aged ; Protein Kinase Inhibitors / adverse effects ; Protein Kinase Inhibitors / therapeutic use* ; Proto-Oncogene Proteins c-ret / antagonists & inhibitors* ; Proto-Oncogene Proteins c-ret / genetics* ; Pyrazoles / adverse effects ; Pyrazoles / therapeutic use* ; Pyridines / adverse effects ; Pyridines / therapeutic use* ; Pyrimidines / adverse effects ; Pyrimidines / therapeutic use* ; Time Factors ; Treatment Outcome
Abstract
Background: Oncogenic alterations in RET have been identified in multiple tumour types, including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.

Methods: ARROW is a multi-cohort, open-label, phase 1/2 study done at 71 sites (community and academic cancer centres) in 13 countries (Belgium, China, France, Germany, Hong Kong, Italy, Netherlands, Singapore, South Korea, Spain, Taiwan, the UK, and the USA). Patients aged 18 years or older with locally advanced or metastatic solid tumours, including RET fusion-positive NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-2 (later limited to 0-1 in a protocol amendment) were enrolled. In phase 2, patients received 400 mg once-daily oral pralsetinib, and could continue treatment until disease progression, intolerance, withdrawal of consent, or investigator decision. Phase 2 primary endpoints were overall response rate (according to Response Evaluation Criteria in Solid Tumours version 1·1 and assessed by blinded independent central review) and safety. Tumour response was assessed in patients with RET fusion-positive NSCLC and centrally adjudicated baseline measurable disease who had received platinum-based chemotherapy or were treatment-naive because they were ineligible for standard therapy. This ongoing study is registered with ClinicalTrials.gov, NCT03037385, and enrolment of patients with treatment-naive RET fusion-positive NSCLC was ongoing at the time of this interim analysis.

Findings: Of 233 patients with RET fusion-positive NSCLC enrolled between March 17, 2017, and May 22, 2020 (data cutoff), 92 with previous platinum-based chemotherapy and 29 who were treatment-naive received pralsetinib before July 11, 2019 (efficacy enrolment cutoff); 87 previously treated patients and 27 treatment-naive patients had centrally adjudicated baseline measurable disease. Overall responses were recorded in 53 (61%; 95% CI 50-71) of 87 patients with previous platinum-based chemotherapy, including five (6%) patients with a complete response; and 19 (70%; 50-86) of 27 treatment-naive patients, including three (11%) with a complete response. In 233 patients with RET fusion-positive NSCLC, common grade 3 or worse treatment-related adverse events were neutropenia (43 patients [18%]), hypertension (26 [11%]), and anaemia (24 [10%]); there were no treatment-related deaths in this population.

Interpretation: Pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC.

Funding: Blueprint Medicines.
Full Text
https://www.sciencedirect.com/science/article/pii/S1470204521002473
DOI
10.1016/S1470-2045(21)00247-3
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184725
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links